IRCCS Istituto Auxologico, U.O. Eating Disorder "San Giuseppe" Hospital, Verbania, Italy,
Psychiatr Danub. 2021 Sep;33(Suppl 9):63-68.
The pharmacological approach to eating disorders (ED) is effective in a few conditions, and to date, no treatment has shown certain efficacy in treating patients with this disorder. Furthermore, attempts to regulate hunger and satiety through modulation pharmacological effects of neurotransmitters and neuropeptides have shown only short-term benefit. However, in light of the serious impact of DCA on patients and the scarcity of non-pharmacological therapeutic approaches, research in this area should not be abandoned, also because new generation "molecules" become increasingly available. Many studies looked at efficacy of antipsychotics, Tryciclics, SSRI, mood stabilizers in the treatment of ED. Gabaergic circuit, the opioid one are extremely involved in the neurohormonal mechanisms of regulation of dietary behaviors and that molecules that influence these circuits could be used in the pharmacological treatment of ED as already happens in the case of Naltrexone, gabapentine or gabaergic drugs.
药物治疗进食障碍（ED）在某些情况下是有效的，但迄今为止，尚无治疗方法被证明对治疗这种疾病的患者具有确切疗效。此外，通过调节神经递质和神经肽的药理学作用来调节饥饿感和饱腹感的尝试仅显示出短期益处。然而，鉴于 DCA 对患者的严重影响以及非药物治疗方法的稀缺性，不应放弃该领域的研究，这也是因为新一代“分子”越来越多。许多研究都着眼于抗精神病药、三环类抗抑郁药、SSRIs、心境稳定剂治疗 ED 的疗效。GABA 能回路、阿片能回路在调节饮食行为的神经激素机制中起着至关重要的作用，因此，影响这些回路的分子可以被用于 ED 的药物治疗，就像已经在纳曲酮、加巴喷丁或 GABA 能药物的情况下那样。
